Therapeutic Landscape and Future Direction of Metastatic Colorectal Cancer

In patients with deficient mismatch repair and BRAFV600E metastatic colorectal cancer, randomized phase III trials have established the efficacy of pembrolizumab as first-line therapy and the combination of encorafenib and cetuximab as second-line or third-line therapy.